Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Clinical Study to Investigate the Safety and Immunogenicity of the Sing2016 (A/Singapore/INFIMH-16-0019/2016) M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old.

NCT04785794 is registered in ClinicalTrials.gov with FluGen Inc as lead sponsor.

NCT NCT04785794
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04785794 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Clinical Study to Investigate the Safety and Immunogenicity of the Sing2016 (A/Singapore/INFIMH-16-0019/2016) M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old.
Lead sponsor
FluGen Inc
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2021
Completion date
November 30, 2021
Enrollment
122 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

influenza vaccine